Leap Therapeutics, Inc. (LPTX) Earnings History
Net Loss14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Leap Therapeutics, Inc. (LPTX) Earnings Overview
As of June 29, 2026, Leap Therapeutics, Inc. (LPTX) reported trailing twelve-month net income of -$57M, reflecting +103.8% year-over-year growth. The company earned $-0.34 per diluted share over the past four quarters.
Looking at the long-term picture, LPTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $5M in fiscal 2025, representing a new all-time high.
Leap Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), AGEN ($65M net income, 0.1% margin), TGTX ($462M net income, 72.6% margin), LPTX has comparable earnings metrics. Compare LPTX vs IMVT →
LPTX Earnings vs Peers
Earnings metrics vs comparable public companies
LPTX Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5M | +107.1% | -$37M | $0.07 | - | - |
| 2024 | -$68M | +17.0% | -$70M | $-1.81 | - | - |
| 2023 | -$81M | -49.1% | -$87M | $-3.98 | - | - |
| 2022 | -$55M | -34.5% | -$57M | $-4.82 | - | - |
| 2021 | -$41M | -1098.3% | -$41M | $-4.73 | -2705.8% | -2761.7% |
| 2020 | -$3M | +1.7% | -$3M | $-4.64 | -33.7% | -34.3% |
| 2019 | -$3M | +85.1% | -$3M | $-14.57 | -35.6% | -35.9% |
| 2018 | -$23M | +22.2% | -$31M | $-16.05 | - | - |
| 2017 | -$30M | -16.0% | -$32M | $-32.35 | - | - |
| 2016 | -$26M | -21.5% | -$28M | $-27.29 | - | - |
| 2015 | -$21M | +17.1% | -$21M | $-12.37 | - | - |
| 2014 | -$25M | -38.9% | -$21M | $-21.45 | - | - |
| 2013 | -$18M | -136.3% | -$14M | $-24.62 | - | - |
| 2012 | -$8M | - | -$9M | $-10.42 | - | - |
Download Data
Export LPTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LPTX — Frequently Asked Questions
Quick answers to the most common questions about buying LPTX stock.
What is LPTX earnings per share (EPS)?
LPTX trailing twelve-month (TTM) diluted EPS is $-0.34, reflecting +103.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Leap Therapeutics, Inc.'s net income?
Leap Therapeutics, Inc. (LPTX) trailing twelve-month net income is $-57M as of 2025. Earnings grew +103.8% year-over-year.
Is LPTX profitable?
LPTX is not currently profitable on a TTM basis, reporting a net loss of $-57M. Net margin is N/A. Investors should monitor for a return to profitability.
What is LPTX's earnings growth rate?
LPTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are LPTX's profit margins?
Leap Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is +5.1%.
Is LPTX growing earnings?
Yes, LPTX earnings are accelerating — EPS growth of +103.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-57M. Earnings momentum is strengthening.
What was LPTX's best earnings year?
Leap Therapeutics, Inc.'s highest annual net income on record is $5M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were LPTX's earnings last quarter?
LPTX's most recent reported quarter was Q1 2026. Net income was $-77M with diluted EPS of $-0.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.